Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.

Abstract: Compositions that include at least a portion of a flagellin and an antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to infection.

Abstract: The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Abstract: Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.

Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.

Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.

Abstract: Adjuvant compositions comprising specific 5mer polypeptides in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.

Abstract: Disclosed is an alkaline extract of shredded pinecones yields a polyphenylpropanoid polysaccharide complex (PPC) that functions as an orally active immune adjuvant. Specifically, the oral PPC boosts the number of antigen-specific memory CD8+ T cells generated in response to a variety of vaccine types (DNA, protein, and dendritic cell) and bias the response towards one that is predominately a T helper 1 type. The oral PPC has potential for use be to enhance the T cell response generated by a variety of prophylactic and therapeutic vaccines designed to target a cellular response.

Abstract: An antigenic composition comprising an antigen and an effective adjuvant, the adjuvant comprising isolated or recombinant YscF, a YscF fragment, truncated YscF (trYscF), or homologs thereof. A method of inducing an enhanced immune response comprising administering an antigen and an effective adjuvant comprising isolated or recombinant YscF, a YscF fragment, trYscF, or homologs thereof. An antigenic composition produced by a process comprising providing a host cell with an expression vector containing a nucleotide sequence encoding YscF, a YscF fragment, trYscF, or YscF homolog capable of acting as an adjuvant; expressing the nucleotide sequence in the host cell to produce the protein; and mixing the collected protein with a suitable excipient.

Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.

Abstract: A method for treating or preventing an inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a compound that inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) signaling.

Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

Abstract: The invention provides a process for producing a composition comprising natural alumino-silicate minerals having improved reactivity for use in methods of animal husbandry, veterinary and pharmaceutical treatment, comprising irradiating natural alumino-silicate minerals in a liquid suspension with transverse electromagnetic wave radiation in the range of 1,800 MHz to 3,000 MHz, the liquid suspension having a boiling temperature of below 120° C. The invention also provides a method of treating digestive ailments in animals comprising administering to an animal in need of same an effective amount of a composition comprising at least one natural alumina-silicate mineral which has been irradiated with transverse electromagnetic wave radiation in the range of 1,800 MHz to 3,000 MHz.

Abstract: Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.

Abstract: The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to new anticancer agents based on miliusane compounds. The present invention also includes its preparation and application method for treating cancer.

Abstract: The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.

Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.

Abstract: The present invention relates to stabilized pharmaceutical formulations prepared from solutions comprising an antineoplastic compound having a cyclic or non-cyclic hydrazine, triazine, or tetrazine group, or a pharmaceutically acceptable salt thereof, and a stabilizer, wherein the stabilizer is an antioxidant and/or more susceptible to nucleophilic attack than the antineoplastic compound.

Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.

Abstract: Described are lyophilized compositions comprising cidofovir, hydroxypropyl methylcellulose (HPMC) or hydroxyethylcellulose (HEC) and, optionally, a plasticizer. In particular, described are such compositions that form a sheet-shaped porous solid matrix. Also described are methods for producing such compositions and their use in treating human papillomavirus (HPV) infections and HPV-associated malignancies, in particular, HPV lesions and cervical cancer.

Abstract: Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo molecule. The vehicle effectively delivers the cargo molecule systemically throughout the tissues of the body including into the central nervous system.

Abstract: This invention relates to a peptide or polypeptide (a) which is esterified or thio-esterified (i) at the carboxylate of the C-terminus with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (ii) at a side-chain carboxylate of one or more Asp or GIu residues, if present, with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (iii) at a hydroxyl group of one or more Ser, Thr or Tyr residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; (iv) at a sulfhydryl group of one or more Cys residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; and/or (v) at the N-terminus with a guanidinium alkanoi

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.

Abstract: Provided are an siRNA-polymer conjugate, and a method for preparing the same, and more specifically, to a hybrid conjugate formed by covalently bonding siRNA and a polymeric compound for improving the in vivo stability of siRNA, and to a preparation method of the hybrid conjugate. The conjugate of the present invention can improve the in vivo stability of siRNA, thereby achieving an efficient delivery of therapeutic siRNA into cells and exhibiting the activity of siRNA even with a small dose of a relative low concentration. Therefore, the conjugate can advantageously be used as not only an siRNA treatment tool for cancers and other infectious disease, but also a novel type siRNA delivery system.

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.

Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.

Abstract: The present invention is a targeted drug delivery composition composed of carrier-linked magnetic nanoparticles. Using an alternating magnetic field, nanoparticles bound to a targeted cell are selectively ruptured thereby releasing therapeutic agents at the desired site of action.

Abstract: The present invention relates to a safe and effective way to deliver and express therapeutic compositions (e.g., transgenes) to the pancreas and lungs of a mammal.

Abstract: Gas-filled microvesicles associated with a polypeptide comprising a sequence of amino acids, said sequence exhibiting binding affinity for selectins, particularly p-selectin. The gas-filled microvesicles can be used in ultrasound imaging.

Abstract: Embodiments provide dual modality probes for imaging phosphatidylserine (PS) exposure and other anionic membrane surfaces. In various embodiments, the probes were constructed by utilizing a) the high selectivity of synthetic zinc (II) dipicolylamine coordination complexes (Zn-DPA) for targeting externalized PS which over-expresses in apoptotic and necrotic cells, b) a near-infrared (NIR) dye for optical imaging, and c) a widely used clinically approved radionuclide for PET (or SPECT) imaging. A variety of linking elements were incorporated into the probes between the Zn-DPA and radionuclide motif to modulate the pharmacokinetics. The in vitro and in vivo data of radiolabeled dipicolylamine probes demonstrated their utilities for imaging PS exposure with multiple imaging modalities.

Abstract: A compound represented by the following formula (1), or a salt thereof: wherein R1 is a radioactive halogen substituent, 0 to 2 of A1, A2, A3 and A4 represent N, and the rest represent —(CH)— is effective as a diagnostic imaging probe targeting amyloid. A diagnostic agent for Alzheimer's disease contains a compound represented by the above formula (1) or a salt thereof. After administration to a patient, the compound and the diagnostic agent for Alzheimer's disease transfer into the patient's brain, and indicate good accumulation on amyloid deposited in the brain.

Abstract: A method for flow-through aqueous liquid sterilization which employs apparatus operating at substantially fixed temperatures and pressures and variable flow rates through the apparatus for controllably processing aqueous liquids to achieve predetermined values of Sterility Assurance Levels (SAL's).

Abstract: The shoe sole sanitizer provides a UV radiation emitting system that kills microbial pathogens deposited on shoe sole surfaces. The system includes a housing containing at least one UV radiation source. Bottom and side portions of the housing are opaque to provide a UV shield while directing the UV upward towards a top housing portion. The top housing portion has a plurality of holes forming an approximate shape of two shoe sole bottoms. The holes allow the UV radiation to escape the housing and target sole surfaces disposed on and over the exterior of the housing top. Each shoe sole approximation area has a pivotal tang that extends therefrom. Shutters attached internally to the tangs extend or limit UV exposure from the top surface depending on the size of the sole disposed on the top. The system is powered by standard AC electrical power or battery sources.

Abstract: Disclosed is a filtering device for a bidet, including a base, a blower sucking air into the bidet, a filter casing mounted to the base, a phytoncide filter unit contained in the filter casing, a door opening and closing the filter casing, and a duct connecting the blower and the filter casing.

Abstract: A system for decontaminating an enclosure that defines a region. The system includes a decontamination unit for generating a vaporized sterilant. The decontamination unit includes a housing that defines a chamber therein. An inlet and an outlet of the housing fluidly communicate with the chamber. A bulkhead assembly connects the decontamination unit to the enclosure. The bulkhead assembly includes a barrier assembly for sealing an opening of the enclosure. The membrane traverses the opening of the enclosure. A first port and a second port allow the carrier gas to flow through the membrane. A frame assembly seals the barrier assembly into the opening of the enclosure. An outlet conduit defines a flow path for conveying the carrier gas from the decontamination unit to the region of the enclosure. A return conduit defines a flow path for conveying the carrier gas from the enclosure to the decontamination unit.

Abstract: A scent warmer has a base structure including a lower portion and a scented material-holding portion. The lower portion may include at least one sidewall and be at least substantially hollow. An electrical heat source and a filamentless electrical light source may be disposed in the base structure lower portion. The scent warmer may include a power supply input element for providing electrical power to the electrical heat source and the filamentless electrical light source. Methods of the invention may include methods of warming a scented material and methods of forming a scent warmer.

Abstract: Ink jet delivery systems for a fluid composition comprising from about 50% to about 100%, by weight of the composition, of an active mixture. The active mixture having a vapor pressure less than about 2.3 kPa at 20 C. The composition also comprising about 0% to 50%, by weight, of a carrier volatile composition having a vapor pressure above about 2.3 kPa at 20 C and an ink jet head for delivering the fluid composition into the air.

Abstract: The present invention provides a pump type aroma diffuser including an essential oil bottle for containing essential oil and a gasification assembly connected with an open end of the essential oil bottle. The gasification assembly includes a gasification cavity, as well as an air nozzle and an essential oil nozzle which are installed on the cavity wall of the gasification cavity. The air nozzle and the essential oil nozzle are interconnected with the gasification cavity. The pump type aroma diffuser also includes a guide assembly which covers the gasification cavity and is configured to guide aroma. The guide assembly has a concentrated fog outlet for exhausting aroma, a first intake backflow channel and a second intake backflow channel which extend from the concentrated fog outlet to two different directions. The tail ends of the first intake backflow channel and the second intake backflow channel extend into the gasification cavity.

Abstract: Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed.

Abstract: Described is an implantable medical material comprising a malleable, cohesive, shape-retaining putty including mineral particles, insoluble collagen fibers and soluble collagen. The medical material can be used in conjunction with biologically active factors such as osteogenic proteins to treat bone or other tissue defects in patients.

Abstract: A method for producing a bone matrix scaffold has the steps of providing at least one sheet material and cross-linking the at least one sheet material using fibers. The sheet material has a surface pattern that enhances osteo-conductivity and potentially supports inductivity. The surface pattern is a 3-dimensional substantially continuous network having voids. The combination of the at least one sheet and fibers form a macrostructure having substantially continuous network and voids.

Abstract: This invention relates to processes of preparing heterogeneous graft material from animal tissue. Specifically, the invention relates to the preparation of animal tissue, in which the tissue is cleaned and chemically cross-linked using both vaporized and liquid cross-linking agents, resulting in improved physical properties such as thin tissue and lowered antigenicity, thereby increasing the ease of delivering the tissue during surgery and decreasing the risk of post-surgical complication, respectively.

Abstract: A connective tissue scaffold including opposed first and second anchoring segments formed from a plurality of bioresorbable polymeric fibers oriented in a direction substantially parallel to a longitudinal axis of the scaffold and a plurality of bioresorbable polymeric fibers oriented in a direction substantially transverse to a longitudinal axis of the scaffold. A central segment joins the first and second anchoring segments and includes a plurality of bioresorbable polymeric fibers oriented in a direction substantially parallel to the longitudinal axis of the scaffold. The scaffold can also a tissue particle and/or biological component.

Abstract: Controlled release vascular implants, such as vascular grafts, stents, wraps, and gels comprising a biocompatible polymer and all trans retinoic acid (ATRA), or its derivatives, can be used to treat, prevent, or inhibit thrombosis and/or neointimal hyperplasia which may otherwise be induced by prosthetic implantation. In particular, the implants herein can inhibit smooth muscle cell proliferation, neointimal hyperplasia, and upregulate antithrombotic genes and nitric oxide production in the vasculature. Further, the implants are capable of delivering controlled and predictable localized concentrations of ATRA.

Abstract: The invention relates to a connection device for merging at least two line sections in a vacuum-based wound treatment system, wherein the two line sections are arranged on the wound side in relation to the connection device, and wherein the connection device, on the side thereof facing away from the wound, can be connected to a third, multi-lumen line section leading to a vacuum-generating device; the connection device is designed, according to the invention, such that the at least two line sections have a multi-lumen configuration and these line sections each have a multi-lumen attachment device that can be brought into flow communication with the connection device, and such that separate lumens of the two line sections on the wound side also remain separate from each other inside the connection device and inside the third line section.

Abstract: A wound treatment apparatus is provided for treating tissue damage, which comprises a fluid impermeable wound cover sealed over a site for purposes of applying a reduced pressure to the site. The apparatus also can include a cover with protrusions on its surface for purposes of monitoring pressure at the site. One or more sensors can be positioned under the cover to provide feedback to a suction pump controller. The apparatus can have a miniature and portable vacuum source connected to the wound cover.

Abstract: A nursing bra for monitoring a child's milk intake during breast feeding procedures preferably includes a body adapted to be worn about a user breast, an electronic scale attached to the body for detecting a weight of the user breast, a monitor communicatively coupled to the electronic scale for receiving the weight of the user breast, a power source communicatively coupled to the scale and the monitor respectively. In this manner, the monitor displays a weight of the user breast before and after breast feeding procedures.

Abstract: A cannula assembly, further comprising a cannula body for directing blood from the heart of a patient, having distal and proximal ends and a lumen therebetween. A tip coupled to the distal end of the body, the tip having an opening. A pump for drawing blood into the cannula assembly and dispensing the blood from the cannula assembly and into the patient circulatory system. The lumen of the cannula body further comprises a first inner diameter at the proximal end and a second inner diameter at the distal end, the first inner diameter being larger than the second inner diameter. A tapered portion defined as a decrease in inner diameter from the first inner diameter to the second inner diameter between the proximal and distal ends, the tapered portion configured to prevent cavitation of the blood within the cannula.

Abstract: A heart assist device comprising a rotary pump housing having a cylindrical bore, a pumping chamber and a motor stator including an electrically conductive coil located within the housing and surrounding a portion of the cylindrical bore. A rotor has a cylindrical shaft, at least one impeller appended to one end of the shaft, and a plurality of magnets located within the shaft. The rotor shaft is positioned within the housing bore with the magnets opposite the motor stator, and the impeller is positioned within the pumping chamber. The housing bore is closely fitted to the outer surface of the shaft forming a hydrodynamic journal bearing, with the pumping chamber and journal bearing connected by a leak path of blood flow between the pumping chamber and the journal bearing. A backiron of the motor stator attracts the rotor magnets to resist longitudinal displacement of the rotor within the housing during operation.